Symbols

SVA

Sinovac Biotech·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SVA

Sinovac Biotech Ltd.

A China-based biopharmaceutical company focuses on vaccines that protect against human infectious diseases

Industry

Biological Technology

Established Date

03/01/1999

Listing Date

11/16/2009

Exchange

NASDAQ Stock Exchange

Full-time Employees

3,037

Fiscal Year Ends

12-31

Website

www.sinovac.com

Security Type

Common stock

Office address

No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China

Business

Research, development, production and commercialization of vaccines for the prevention of hepatitis, hepatitis B, influenza, etc

Introduction

Sinovac Biotech Ltd. was incorporated in Antigua and Barbuda on March 1, 1999. It is a bio-high-tech enterprise headquartered in Beijing. The company is principally engaged in the research, development, manufacture and protection of vaccines against infectious diseases. The company has also developed the world's first inactivated SARS coronavirus vaccine (completed Phase I clinical study), China's first pandemic influenza (H5N1) vaccine, and the world's first H1N1 influenza vaccine, contributing to disease prevention and control in China and the world. The company is developing a series of new products, including Sabin strain inactivated polio vaccine, 23-valent pneumococcal polysaccharide vaccine, new coronavirus inactivated vaccine and multiple combination vaccines.

Company Financials

EPS

SVA has released its 2020 Q4 earnings. EPS was reported at 0.96, versus the expected 0, beating expectations. The chart below visualizes how SVA has performed over recent quarters, highlighting trends in earnings surprises.